Akcea Therapeutics, a spinout and subsidiary of Carlsbad drugmaker Ionis Pharmaceuticals, has asked for the green light from regulators to sell one of its drugs in Canada.

The investigational therapy, called volanesorsen, is meant to treat a rare and sometimes fatal genetic condition called familial chylomicronemia syndrome, or FCS, which causes a buildup of fats in the blood that can cause severe abdominal pain.

Canada is the third global market for which Akcea has filed regulatory paperwork, with requests submitted in the U.S. and European Union earlier this year. If approved in these markets, sales of the drug could begin sometime next year.

Akcea, based in Boston, went public in June, raising $100 million to develop four drugs based off of Ionis’ “antisense” technology. It’s possible that Akcea’s pipeline could be a significant source of royalty revenue for Ionis, should the medicine pass regulatory review.

Canada has given the drug a priority review, which should speed the drug’s path to market.